Nov. 1-2, 2023
Uniform Formulary Request for Quote Information
- UF BPA & UF ADP RFQ Documents Posted: July 19, 2023
- Pre-Proposal Teleconference: Aug. 9, 2023 at 1 p.m. CT
- UF BPA & UF ADP Class Quotes Due: Sept. 8, 2023 at 12 p.m. CT
*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.
| Class Review |
Designated Newly Approved Drugs |
Drugs in Previously Reviewed Classes |
- MIGRAINE AGENTS - CGRP CLUSTER HEADACHE:
- MIGRAINE AGENTS - CGRP PREVENTATIVE:
-
Aimovig
-
Ajovy
-
Emgality 120mg/ml
- NEUROLOGICAL AGENTS MISCELLANEOUS - MOVEMENT DISORDERS:
-
Austedo
-
Austedo XR
-
Ingrezza
|
-
Airsupra
-
Brenzavvy
-
Cyltezo
-
Hadlima
-
Hulio + unbranded biologic
-
Hyrimoz + unbranded biologic
- Lyuzeh
-
Lodoco
-
Ngenla
-
Olpruva
-
Opvee
-
Sohonos
-
Suflave
-
Vanflyta
-
Xdemvy
-
Yuflyma
-
Yusimry
|
|
Aug. 2-3, 2023
Uniform Formulary Request for Quote Information
- UF BPA & UF ADP RFQ Documents Posted: April 20, 2023
- Pre-Proposal Teleconference: May 10, 2023 at 1 p.m. CT
- UF BPA & UF ADP Class Quotes Due: June 15, 2023 at 12 p.m. CT
*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.
| Class Review |
Designated Newly Approved Drugs |
Drugs in Previously Reviewed Classes |
- LUTEINIZING HORMONE-RELEASING HORMONE AGONISTS-ANTAGONISTS - PROSTATE CANCER AGENTS:
-
Camcevi
-
Eligard
-
Firmagon
-
Leuprolide Depot 22.5mg
-
Lupron Depot 7.5mg, 22.5mg, 30mg, and 45mg
-
Orgovyx
- LUTEINIZING HORMONE-RELEASING HORMONE AGONISTS-ANTAGONISTS - CENTRAL PRECOCIOUS PUBERTY AGENTS:
-
Fensolvi
-
Lupron Depot-Ped
- LUTEINIZING HORMONE-RELEASING HORMONE AGONISTS-ANTAGONISTS - ENDOMETRIOSIS/FIBROIDS AGENTS:
-
Lupron Depot 3.75mg & 11.25mg
-
Myfembree
-
Oriahnn
-
Orilissa
- WHITE BLOOD CELL STIMULANTS - FILGRASTIM:
- Granix
-
Neupogen
-
Nivestym
-
Releuko
-
Zarxio
- WHITE BLOOD CELL STIMULANTS - PEGFILGRASTIM:
- Fulphila
- Fylnetra
- Neulasta
- Neulasta Onpro
- Nyvepria
- Stimufend
- Udenyca
- Ziextenzo
|
-
Atropine Sulfate 1% Opt
-
Austedo XR
-
Cuvrior
-
Inpefa
-
Joenja
-
Liqrev
-
Lumryz
-
Miebo Opt
-
Skyclarys
-
Sogroya
-
Veozah
-
Vowst
-
Zavzpret
-
Zolpidem Tartrate 7.5mg Cap
|
|
May 3-4, 2023
Uniform Formulary Request for Quote Information
- UF BPA & UF ADP RFQ Documents Posted: Jan. 27, 2023
- Pre-Proposal Teleconference: Feb. 1, 2023 at 1 p.m. CT
- UF BPA & UF ADP Class Quotes Due: March 20, 2023 at 12 p.m. CT
*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.
| Class Review |
Designated Newly Approved Drugs |
Drugs in Previously Reviewed Classes |
- ANTILIPIDEMICS-1 - PCSK9:
- OPHTHALMIC - DRY EYE:
-
Cequa
-
Eysuvis
-
Restasis
-
Tyrvaya
-
Xiidra
-
Verkazia
|
-
Amjevita
-
Altuviiio
-
Atorvaliq
-
Daybue
-
Filspari
-
Jaypirca
-
Konvomep
-
Krazati
-
Orserdu
-
Pradaxa Pellets
-
Rezvoglar
-
Stimufend
-
Tezspire
|
|
Feb. 8-9, 2023
Uniform Formulary Request for Quote Information (Class Nephrology Misc.)
- UF BPA & UF ADP RFQ Documents Posted: Dec. 2, 2022
- Pre-Proposal Teleconference: Dec. 7, 2022 at 1 p.m. CT
- UF BPA & UF ADP Class Quotes Due: Jan. 20, 2023 at 12 p.m. CT
Uniform Formulary Request for Quote Information (Class Androgens Anabolic Steroids and Sleep Disorders)
- UF BPA & UF ADP RFQ Documents Posted: Oct. 24, 2022
- Pre-Proposal Teleconference: Nov. 9, 2022 at 1 p.m. CT
- UF BPA & UF ADP Class Quotes Due: Dec. 14, 2022 at 12 p.m. CT
*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.
| Class Review |
Designated Newly Approved Drugs |
Drugs in Previously Reviewed Classes |
- ANDROGENS-ANABOLIC STEROIDS - TESTOSTERONE REPLACEMENT THERAPIES:
- Androderm
- Jatenzo
- Kyzatrex
- Methitest
- Natesto
- Testim
- Testred
- Tlando
- Xyosted
- SLEEP DISORDERS - DUAL OREXIN RECEPTOR ANTAGONISTS:
- NEPHROLOGY AGENTS MISCELLANEOUS – NA:
|
-
Auvelity
-
Basaglar Tempo Pen
-
Ermeza
-
Furoscix
-
Fylnetra
-
Humalog Tempo Pen
-
Leuprolide Depot
-
Lytgobi
-
Lyumjev Tempo Pen
-
Noxafil
-
Relyvrio
-
Rezlidhia
-
Xelstrym
|
|